Image

Feasibility Study of a New Immunoglobulin E (IgE) Assay Method

Feasibility Study of a New Immunoglobulin E (IgE) Assay Method

Recruiting
6-99 years
All
Phase N/A

Powered by AI

Overview

The main objective is to study the feasibility of a new specific IgE assay using a bioluminescence technique in a pediatric and adult allergic population. For this, we will collect blood, and urine during a blood test scheduled for the follow-up of the patient.

Description

Allergy is a raising public health problem. Specific IgE assays are useful tools to investigate the physiopathology of allergies. This method is achieved mainly by the ImmunoCAP enzyme immunoassay technique. This is an expensive test that requires a significant amount of blood. This is a limitation particularly in children. The time to get the results is long and a second consultation has to be scheduled in order to communicate the results to the patients. The main objective of this study is to assess the feasibility of a new specific IgE assay, named LuLISA, using a bioluminescence technique in urine and blood samples from pediatric and adult allergic population. This technique was recently published for the quantification of IgE against two peanut allergens and needs to be extended for the detection of other major allergens. A secondary objective is the evaluation of the time needed to obtain results.

Eligibility

Inclusion Criteria:

  • Males or females 6 months' old or older
  • Sensitization or allergy towards a trophallergen, an aeroallergen, hymenoptera venom or drug proven by:
    • positive skin test (s)
    • and / or IgE specific (s)> 0.1 kUA / L
    • and / or anamnesis in favor of an allergic reaction of mediated IgE
  • Social coverage up to date

Exclusion Criteria:

  • Children younger than 6 months'old
  • Children's weight less than 10 kg
  • Pregnant or breastfeeding women
  • Patients with cystic fibrosis
  • Patients with dysimmune or autoimmune pathology
  • Anamnesis in favor of a delayed allergy or a contact allergy.

Study details
    Allergy and Immunology

NCT04751760

University Hospital, Toulouse

16 April 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.